A biotechnology firm develops a novel antibiotic targeting
highly drug‑resistant pathogens. Although current therapies can
treat these infections, they are limited by significant adverse effects and
growing resistance. For its phase III clinical evaluation, the company designs
a non‑inferiority
trial rather than attempting to show that the new agent is more effective than
standard therapy.

What is the most appropriate justification for this trial
design?

Question

A biotechnology firm develops a novel antibiotic targeting
highly drug‑resistant pathogens. Although current therapies can
treat these infections, they are limited by significant adverse effects and
growing resistance. For its phase III clinical evaluation, the company designs
a non‑inferiority
trial rather than attempting to show that the new agent is more effective than
standard therapy.

What is the most appropriate justification for this trial
design?

Answer

Non‑inferiority studies are preferred mainly because
they are faster and cheaper to conduct

Answer

Superiority
trial designs are not permitted by regulatory authorities for antibiotics

Answer

Showing
similar effectiveness is acceptable when the new drug provides additional
benefits such as lower toxicity or improved resistance coverage

Answer

Resistant
bacterial infections occur too rarely to power a superiority trial

Crowdly

A biotechnology firm develops a novel antibiotic targeting highly drug‑resistan...

Want instant access to all verified answers on learning.monash.edu?